Ipragliflozin: Difference between revisions
CSV import |
CSV import |
||
| Line 24: | Line 24: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Ipragliflozin_structure.svg|Chemical structure of Ipragliflozin | |||
File:Haworth_projection_of_ipragliflozin.svg|Haworth projection of Ipragliflozin | |||
</gallery> | |||
Latest revision as of 01:30, 18 February 2025
Ipragliflozin is an antidiabetic drug that is used in the treatment of type 2 diabetes. It belongs to the class of drugs known as SGLT2 inhibitors, which work by preventing the kidneys from reabsorbing glucose back into the blood, thereby promoting the excretion of glucose in the urine.
Etymology[edit]
The name "Ipragliflozin" is derived from the chemical structure of the drug. The "Ipra-" prefix is derived from the chemical name "Ipragliflozin", and the "-gliflozin" suffix is common to all drugs in the SGLT2 inhibitor class.
Pharmacology[edit]
Ipragliflozin works by inhibiting the SGLT2 protein in the kidneys. This protein is responsible for reabsorbing glucose from the urine back into the blood. By inhibiting this protein, Ipragliflozin promotes the excretion of glucose in the urine, thereby lowering blood glucose levels.
Clinical Use[edit]
Ipragliflozin is used in the treatment of type 2 diabetes. It is often used in combination with other antidiabetic drugs, such as metformin, to improve glycemic control in patients who are not adequately controlled on metformin alone.
Side Effects[edit]
Like all drugs, Ipragliflozin can cause side effects. The most common side effects include urinary tract infections, genital infections, and increased urination. Less common but more serious side effects include ketoacidosis, a serious condition that can occur if the body starts to break down fat too quickly.
